Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more
Roche Holding AG (RHHBF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: 0.130x
Based on the latest financial reports, Roche Holding AG (RHHBF) has a cash flow conversion efficiency ratio of 0.130x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.95 Billion) by net assets ($30.34 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Roche Holding AG - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Roche Holding AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Roche Holding AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Roche Holding AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Raytheon Technologies Corp
NYSE:RTX
|
0.062x |
|
UnitedHealth Group Incorporated
NYSE:UNH
|
0.011x |
|
Nestle SA
PINK:NSRGF
|
0.168x |
|
Agricultural Bank of China PK
PINK:ACGBY
|
0.324x |
|
The Goldman Sachs Group, Inc.
LSE:0R3G
|
-0.130x |
|
SAP SE
PINK:SAPGF
|
0.028x |
|
Goldman Sachs Group Inc
NYSE:GS
|
-0.130x |
|
Wells Fargo & Company
NYSE:WFC
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Roche Holding AG (2014–2025)
The table below shows the annual cash flow conversion efficiency of Roche Holding AG from 2014 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $37.88 Billion | $18.85 Billion | 0.498x | -10.44% |
| 2024-12-31 | $36.16 Billion | $20.09 Billion | 0.556x | +14.84% |
| 2023-12-31 | $33.26 Billion | $16.09 Billion | 0.484x | -15.88% |
| 2022-12-31 | $32.02 Billion | $18.41 Billion | 0.575x | -22.27% |
| 2021-12-31 | $28.34 Billion | $20.98 Billion | 0.740x | +58.53% |
| 2020-12-31 | $39.77 Billion | $18.57 Billion | 0.467x | -25.21% |
| 2019-12-31 | $35.87 Billion | $22.39 Billion | 0.624x | -5.14% |
| 2018-12-31 | $30.37 Billion | $19.98 Billion | 0.658x | +5.89% |
| 2017-12-31 | $29.01 Billion | $18.02 Billion | 0.621x | +9.36% |
| 2016-12-31 | $26.40 Billion | $15.00 Billion | 0.568x | -13.20% |
| 2015-12-31 | $23.25 Billion | $15.22 Billion | 0.655x | -11.42% |
| 2014-12-31 | $21.68 Billion | $16.02 Billion | 0.739x | -- |